Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-GBM-1 in newly diagnosed glioblastoma
NCT03400917Phase 2Unknown
- Sponsor
- AIVITA Biomedical, Inc.
- Start
- Jun 2018
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AV-GBM-1 in glioblastoma (GBM), sponsored by AIVITA Biomedical, Inc.. Status: unknown.
02
Drugs
AV-GBM-1
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03400917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400917.